Cancer Center Welcomes RefleXion’s SCINTIX Therapy with First Installation at BHCC
RefleXion Medical, a leader in theranostic oncology, has announced that its RefleXion® X1 platform, featuring SCINTIX® biology-guided radiotherapy, will be installed at Beverly Hills Cancer Center (BHCC). This marks the first freestanding cancer center (FSCC) to adopt the RefleXion X1 system.
RefleXion Medical, a leading innovator in theranostic oncology, has announced the scheduled installation of its RefleXion® X1 platform at Beverly Hills Cancer Center (BHCC), marking it as the first freestanding cancer center (FSCC) to incorporate this advanced technology. The system, equipped with SCINTIX® biology-guided radiotherapy, uses the inherent biology of a patient’s tumor to precisely direct radiation to its target, ensuring maximum treatment efficacy while minimizing harm to healthy tissue.
“We are committed to offering the highest quality and most innovative cancer treatments at BHCC, and the installation of the RefleXion X1 is a testament to that commitment,” said Dr. Arash (Ari) Gabayan, Chief of Radiation Oncology and Imaging at BHCC. “By integrating this breakthrough technology into our practice, we will be among the first centers globally to offer patients a new way to treat their cancers using their tumor’s own biology as a guide.”
The RefleXion X1 machine is revolutionizing radiation therapy. Unlike traditional methods that rely on static imaging to guide radiation, the SCINTIX system uses real-time biological data emitted from a patient’s tumor to direct radiation precisely. This allows for dynamic adjustments during treatment. If the tumor moves, the system automatically shifts the radiation to follow, ensuring that the tumor receives its full radiation dose while sparing surrounding healthy tissues.
“This collaboration with BHCC is an exciting milestone for RefleXion,” said Todd Powell, President and CEO of RefleXion. “We are thrilled that BHCC and its renowned cancer physicians are among the first to offer this innovative treatment to patients. Their commitment to providing cutting-edge cancer therapies is invaluable to the field of oncology.”
SCINTIX therapy works by utilizing signals emitted from the cancer cells, which are detected in real-time by the RefleXion X1 system. Prior to treatment, patients are injected with a PET tracer, a unique molecule that cancer cells consume. This tracer emits signals that the X1 detects to identify the tumor’s location, allowing the system to guide radiation delivery precisely to the target. This approach contrasts with conventional radiotherapy, which relies on static images to map out treatment.
The new system’s integration at BHCC is part of a broader movement to increase access to advanced cancer treatments. Beginning in 2025, the Centers for Medicare and Medicaid Services (CMS) will expand reimbursement for SCINTIX therapy. New billing codes will be introduced, offering reimbursement for freestanding cancer centers (FSCCs) and for physicians working in both FSCCs and hospital outpatient departments. This change is expected to help accelerate the adoption of SCINTIX therapy in cancer treatment centers across the country.
“We’re pleased to see CMS expand reimbursement for FSCCs, as it helps clinicians drive the adoption of new, effective treatments,” Powell continued. “This is a crucial step in supporting medical centers like BHCC that are at the forefront of cancer care innovation.”
In collaboration with Select Healthcare Solutions, a provider of turn-key medical technology services, BHCC successfully integrated SCINTIX therapy into its broad range of cancer treatments. This strategic move enhances BHCC’s position as a leader in oncology care, ensuring that patients have access to the latest advances in cancer treatment.
About Beverly Hills Cancer Center (BHCC)
Beverly Hills Cancer Center is a prominent private cancer diagnostic and treatment facility located in Southern California. BHCC offers a unique model of care that integrates advanced clinical trials, state-of-the-art diagnostics, and innovative treatments. The center is home to highly skilled physicians and staff who are dedicated to providing patients with the most effective and personalized care in a comfortable and healing environment.
About RefleXion Medical
RefleXion Medical is pioneering the use of SCINTIX biology-guided radiotherapy to treat cancer. The company’s RefleXion® X1 system allows physicians to deliver precise, real-time radiation to one or more tumors by using signals emitted from the patient’s cancer cells. SCINTIX therapy has been validated for use in FDG-guided treatment of lung and bone tumors, and its potential is being explored for additional indications. RefleXion is also committed to advancing conventional radiotherapy with the X1 system for treating all solid tumors. The company is at the forefront of transforming cancer care with personalized, precise, and effective treatments.
